Mastek Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6p9tyyf8essbx1fh3aa9yliq.pdf

Key Takeaways


Q4 Revenue Miss: The Three US Situations

Chandrana: "This was a disappointing quarter for us from a revenue perspective as well as below our expectation."

Order Book & Deal Wins


Vertical & Geographic Performance

GeographyTrendCommentary
UK▲ StrongUK engine fired well, with good execution partially offsetting US weakness; public sector progress across borders, trade, immigration, and new campaigns around Police Protection and Department of Justice.
Middle East & APAC▲ Growth driverContinued to improve margins while driving growth; taking a more qualified approach targeting larger clients and sustainable deals; expected to keep growing double-digits.
US▼ DisappointingThree specific client situations drove the miss; management expects a strong bounce-back in Q1 as two of the three impacts are transitory.
Europe▬ ImprovingFocus mostly on Oracle Cloud and manufacturing clients; pipeline and deal momentum picked up in H2 FY'24 versus FY'23.
UK Private Sector▲ Early progressSmall base but good progress with the first Bank of England deal; setting up for Financial Services focus.
Chandrana: "We initiated our focus on account mining in FY'23, a little bit 30-second context, as a company organization, we believe we have way too many clients and much more than we actually need and many of our projects and implementation in the past used to essentially kind of conclude and then we moved on to the next client."

Margins: The 16% Blip and Recovery Path

Agarwal: "So, in terms of margin, yes, 16% is a blip to us. Our endeavor is to go back to 17% as we reported in Q3. But at the same time, the focus is more on growth. So, I will keep that range at 17% for now."

Data & AI Positioning


Guidance & Commitments

CommitmentSpecificsTimeline
US revenue recoveryTwo of three transitory client impacts reverse; US bounces back in a very strong wayQ1 FY'25
Revenue run-rate recoveryUS revenue crosses Q3 levelEarly part of Q2 FY'25
Margin recoveryReturn to 17% EBITDA (Q3 level)"Very quickly" (no specific quarter)
Full-year organic growthAspiration to exceed FY'24 organic growth of 12.5-13% in USD termsFY'25
Normalized tax rate27% as a good reference, plus/minus by countryOngoing
Borrowings repaymentContinue to discharge borrowing as plannedNext two to three years
UK public sector campaignsDepartment of Justice, vehicle agency, police protection frameworks expected to crackLater part of FY'25, if not Q2/Q3

Key Metrics

MetricQ4 FY24
Revenue₹779.7 cr, up 9.9% YoY; de-grew 0.6% QoQ in INR and 1.4% in constant currency
Revenue (USD)$93.7 mn, below expectations
Full-year revenue₹3,055 cr, up 19.2% YoY in INR (includes BizAnalytica)
Full-year revenue (USD)$368.4 mn, up 15.8% YoY
Operating EBITDA margin16%, declined 100 bps QoQ; below expectations
Profit after tax₹94.4 cr, up 21% QoQ and 30% YoY; benefited from one-time overseas tax credit
Full-year EBITDA growth11.6% YoY
12-month order book backlog$260 mn, record high; up 5% QoQ and 21% YoY in INR terms
Order book backlog YoY growth19% on a USD basis
Utilization (excl. LEAP)86.5%, improved 110 bps QoQ
Closing headcount5,539, marginal increase of 21 versus December quarter
Gross cash₹473 cr as of March 2024, up from ₹404 cr in December 2023
Borrowings₹487 cr as of March 31, 2024
Dividend₹12 per share recommended, subject to shareholder approval
Top 30 accounts revenue share57% of overall revenue, up from around 50% before account-mining initiative
Customers added22 during the quarter
US Healthcare order book growth (FY24)250% YoY
Fixed-price contract share~30%, down from ~50% historically